´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2022 Fall Semi-annual meeting 2ÀÏÂ÷ : 2022-11-19±³À°ÀÏÀÚ : 2022-11-19
±³À°Àå¼Ò : ¼ÛµµÄÁº¥½Ã¾Æ
±³À°ÁÖÁ¦ :
KGOG 2022 Fall Semi-annual meeting 2ÀÏÂ÷ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ :
kiskgog@hanmail.net ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
ÀÎõ±¤¿ª½Ã±³À°½Ã°£ : 7 ½Ã°£ 5ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-19 Room A 09:00~09:10 Introduction/Review of on-going studies ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)
±³À°½Ã°£ 11-19 Room A 09:10~09:30 Management, Surveillance and Clinical course of Women diagnosed with ±èº¸¶ó(ÀÌ´ë¸ñµ¿º´¿ø)
Åä·Ð 11-19 Room A 09:30~09:40 Discussion ()
±³À°½Ã°£ 11-19 Room A 09:40~10:00 . Randomized Phase III Trial of HIPEC in Platinum-Resistant Recurrent Ovarian ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 11-19 Room A 10:00~10:10 Discussion ()
±³À°½Ã°£ 11-19 Room A 10:10~10:30 Randomized Phase 2 trial of Cytoreductive Surgery for PARPi-Resistant Recurrent Á¶Çö¿õ(°í´ë±¸·Îº´¿ø)
Åä·Ð 11-19 Room A 10:30~10:40 Discussion ()
±³À°½Ã°£ 11-19 Room A 11:00~11:05 Summary & Update of KGOG 1047/DEBULK ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 11-19 Room A 11:05~11:15 New techniques of definitive radiotherapy in cervical cancer : does it matter? ¾ö±Ù¿ë(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11-19 Room A 11:15~11:25 Process of RTQC °»ó¿ø(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11-19 Room A 11:25~11:35 Know-how for successful international collaboration ³²º´È£(Ç층½º)
±³À°½Ã°£ 11-19 Room A 11:35~11:45 Future Revision, Troubleshooting & Expected Performance ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 11-19 Room A 12:00~12:25 Latest update of Olaparib in 1L maintenance therapy in advanced ovarian cancer ³ëÀçÈ«(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11-19 Room A 12:25~12:50 Consideration of choosing combination therapy with Olaparib and bevacizumab ÀÌÀ¯¿µ(»ï¼º¼¿ïº´¿ø)
±âŸ 11-19 Room A 13:00~13:03 Introduction À̱ÙÈ£(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 11-19 Room A 13:10~13:20 Review of recent clinical trials in cervical cancer-ESMO Congress 2022 À̼ºÁ¾(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 11-19 Room A 13:20~13:30 Review of recent clinical trials in cervical cancer-NRG 2022 Summer meeting ÀåÇϱÕ(°í´ë¾È»êº´¿ø)
±³À°½Ã°£ 11-19 Room A 13:30~13:40 Review of recent clinical trials in cervical cancer-ASCO 2022 Annual meeting ³ëÁØÈ£(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 11-19 Room A 13:40~13:45 Overview of ongoing study Á¤¿ë¿í(°³²Â÷º´¿ø)
±³À°½Ã°£ 11-19 Room A 13:45~13:50 . KGOG 1043/ENGOT-CX12 A randomized, Open-Lable, Phase 3 Trial of À̼ºÁ¾(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 11-19 Room A 13:50~13:55 . KGOG 1044/SELPAX-1 Multi-center prospective study for human papilloma ±è¹®È«(¿øÀڷº´¿ø)
±³À°½Ã°£ 11-19 Room A 13:55~14:00 . KGOG 1046/AFTER Adjuvant Chemotherapy Versus Radiotherapy For ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 11-19 Room A 14:00~14:05 . KGOG 1047/DEBULK Therapeutic effect of surgical debulking of metastatic ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 11-19 Room A 14:05~14:10 . KGOG 1048 Prediction model for survival and recurrence in early-stage ±è´ë¿¬(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 11-19 Room A 14:10~14:25 . RTQA (Radiation Therapy Quality Assurance) presentation ±è¿ë¹è(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 11-19 Room A 14:25~14:35 . Tisotumab Vedotin for the cervical cancer ¹éÁöÈì(¾ÆÁִ뺴¿ø)
±³À°½Ã°£ 11-19 Room A 14:35~14:45 . Next drugs: Pembrolizum Àü¼·(¼øõÇâõ¾Èº´¿ø)
±³À°½Ã°£ 11-19 Room A 14:45~15:00 . Imiquimod as an alternative treatment for preinvasive lesion of the uterine Á¤¿ë¿í(°³²Â÷º´¿ø)
±âŸ 11-19 Room A 15:00~15:01 Introduction ¼Û¿ëÁß(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 11-19 Room A 15:01~15:06 KGOG 4004(OVsurg-2102-1): A survey on peritonectomy procedure in debulking ±è¸í¼±(¼ººó¼¾Æ®º´¿ø)
±³À°½Ã°£ 11-19 Room A 15:06~15:11 KGOG 4005 (OVsurg-2101): The analysis of the patients who have received ÀÓ¸íö(±¹¸³¾Ï¼¾Å¸)
±³À°½Ã°£ 11-19 Room A 15:11~15:16 KGOG 4006 (OVsurg-2103): The analysis of 90-day postoperative mortality ¼Û¿ëÁß(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 11-19 Room A 15:16~15:21 KGOG 4010 (OVsurg-2108): Assessment of QoL after LAR or visceral peritoneal ¹Ú¼öÁø(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11-19 Room A 15:21~15:31 OVsurg-2109: A Proper intervention of pleural metastasis in stage IV epithelial ÀÌÀºÁö(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 11-19 Room A 16:00~16:15 Summary of study status º¯È°æ(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 11-19 Room A 16:15~16:30 Trial specific RT-QA ±èÈ£Áø(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 11-19 Room A 16:30~16:40 Future direction and strategy of trial ±è¿ë¹è(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 11-19 Room A 17:00~17:25 Optimal management of Febrile Neutropenia of Ovarian Cancer ±èÁöÇü(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 11-19 Room A 17:25~17:50 Treatment of neutropenia in ovarian cancer ¾çÀºÁ¤(¼øõÇâõ¾Èº´¿ø)